Blood Coagulation Testing Market Research Report Information by Product, by Application, by Test Type, by End User, and by Region Industry Forecast to 2032

Description

List of Tables

Blood Coagulation Testing Market Research Report Information by Product (Consumables and Instruments), by Application (Acquired Bleeding Disorders and Inherited Bleeding Disorders), by Test Type (Prothrombin Time Testing, Activated Partial Thromboplastin Time (aPTT) Testing, Fibrinogen Testing, Activated Clotting Time Testing, Platelet Function Tests, and Others), by End User (Hospitals and Clinics, Diagnostic Centers, Ambulatory Care Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World Industry Forecast to 2032

Market Overview

The Blood Coagulation Testing Market was valued at USD 4.51 billion in 2023. The Blood Coagulation Testing Market is expected to increase from USD 4.81 billion in 2024 to USD 7.84 billion by 2032, with a compound annual growth rate (CAGR) of 6.31% over the forecast period (2024-2032).

The rising prevalence of blood-acquired bleeding disorders, as well as increased product launches by market players in the blood coagulation testing market, are the primary drivers of growth. However, voluntary product recalls by market participants, as well as the high cost of coagulation analyzers, are projected to impede worldwide market expansion. Nonetheless, favorable government initiatives related to bleeding disorders and an increasing geriatric population around the world are expected to generate profitable potential for the industry.

The rising prevalence of both acquired and hereditary bleeding diseases, such as hemophilia, von Willebrand Disease, and other related ailments, is driving the growth of the blood coagulation testing market.

Market Segment insights

Consumables and instruments make up the product sector of the Blood Coagulation Testing Market.

The Blood Coagulation Testing Market is segmented by application, which includes both acquired and inherited bleeding diseases.

The Blood Coagulation Testing Market is divided into test types, which include prothrombin time testing, activated partial thromboplastin time (aPTT) testing, fibrinogen testing, activated clotting time testing, platelet function tests, and others.

End-user segments in the Blood Coagulation Testing Market comprise hospitals and clinics, diagnostic centers, ambulatory care centers, and others.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Blood Coagulation Testing market is expanding rapidly, owing to the rising prevalence of coagulation diseases as well as technological and innovative improvements. Furthermore, the region's well-established healthcare infrastructure, technological advancements, and favorable regulatory environment all contribute to the market's growth.

The European Blood Coagulation Testing market accounted for the second-largest market share, owing to strong healthcare infrastructure and supported government health initiatives and financing. Furthermore, the Germany Blood Coagulation Testing supplier is said to have the greatest market share, while the France Blood Coagulation Testing provider is expected to be the fastest growing market in Europe.

The Asia-Pacific Blood Coagulation Testing market is predicted to develop the fastest from 2023 to 2032, owing to increased public awareness of health management and early diagnosis, as well as favorable reimbursement policies for coagulation tests. Furthermore, China Blood Coagulation Testing accounted for the greatest market share, while India Blood Coagulation Testing is expected to be the fastest expanding market in the Asia Pacific region.

Major Players

Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare, Thermo Fisher Scientific Inc., Sysmex Corporation, Werfen, HemoSonics, LLC, Micropoint Biotechnologies Co., Ltd., Helena Laboratories, and Meril Life Sciences Pvt. Ltd. are among the key players in the Blood Coagulation Testing market.

Product Code: MRFR/LS/0464-CR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF BLOOD ACQUIRED BLEEDING DISORDERS
- 4.2.2 RISING PRODUCT LAUNCH BY MARKET PLAYERS
4.3 RESTRAINTS
- 4.3.1 VOLUNTARY PRODUCT RECALL BY MARKET PLAYERS
- 4.3.2 HIGH COST ASSOCIATED WITH COAGULATION ANALYZER
4.4 OPPORTUNITY
- 4.4.1 FAVOURABLE GOVERNMENT INITIATIVES ASSOCIATED WITH BLEEDING DISORDERS
- 4.4.2 GROWING GERIATRIC POPULATION ACROSS THE GLOBE

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL BLOOD COAGULATION TESTING MARKET

6 GLOBAL BLOOD COAGULATION TESTING MARKET, BY PRODUCT

6.1 OVERVIEW
6.2 CONSUMABLES
- 6.2.1 REAGENTS
- 6.2.2 TEST KITS
6.3 INSTRUMENTS

7 GLOBAL BLOOD COAGULATION TESTING MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 ACQUIRED BLEEDING DISORDERS
7.3 INHERITED BLEEDING DISORDERS
- 7.3.1 HEMOPHILIA
- 7.3.2 VON WILLEBRAND DISEASE
- 7.3.3 OTHERS

8 GLOBAL BLOOD COAGULATION TESTING MARKET, BY TEST TYPE

8.1 OVERVIEW
8.2 PROTHROMBIN TIME TESTING
8.3 ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) TESTING
8.4 FIBRINOGEN TESTING
8.5 ACTIVATED CLOTTING TIME TESTING
8.6 PLATELET FUNCTION TESTS
8.7 OTHERS

9 GLOBAL BLOOD COAGULATION TESTING MARKET, BY END USER

9.1 OVERVIEW
9.2 HOSPITALS AND CLINICS
9.3 DIAGNOSTIC CENTERS
9.4 AMBULATORY CARE CENTERS
9.5 OTHERS

10 GLOBAL BLOOD COAGULATION TESTING MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 EXPANSION
- 11.6.2 AGREEMENT
- 11.6.3 PRODUCT LAUNCH
- 11.6.4 APPROVAL
- 11.6.5 AQUISITION
- 11.6.6 PRODUCT RECOGNITION

12 COMPANY PROFILES

12.1 F. HOFFMANN-LA ROCHE LTD.
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 MICROPOINT BIOTECHNOLOGIES CO., LTD.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 KEY STRATEGIES
12.3 HOMOSONICS LLC
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 HELENA LABORATORIES CORPORATION
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
12.5 SYSMEX CORPORATION
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 WERFEN
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 MERIL LIFE SCIENCES PVT. LTD.
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 THERMO FISHER SCIENTIFIC, INC.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 SIEMENS HEALTHINEERS AG
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PROUDCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 SWOT ANALYSIS
- 12.9.6 KEY STRATEGIES

13 DATA CITATIONS